An ophthalmology resident shares insights from experiences across Mexico, Europe, and the US.
Ophthalmology Times: March/April 2026
Immediate flushing of the eye can significantly reduce long-term damage after chemical exposure.
Cases highlight faricimab’s dual VEGF/ANG2 action for severe diabetic macular edema—faster drying, better vision, longer intervals.
Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA at Angiogenesis 2026.
Explore latest RVO care: faricimab, Eylea HD, and biosimilars that cut injection burden and protect vision from macular edema.
Most patients do well on topical therapy, but innovation in IOP-lowering drops remains essential.
Aaron Y. Lee, MD, MSCI, explains how temporal optical coherence tomography modeling may improve longitudinal disease tracking and clinical decision-making at Angiogenesis 2026.
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Eyes on May 2026: A month of durable therapies, a regulatory reversal, and rethought echanisms
2
TECNIS PureSee IOL launches in US following FDA approval for cataract surgery
3
Dompé initiates phase 3 Orunea trial of cenegermin-bkbj in PCED
4
Heidelberg Engineering announces FDA clearance for new SPECTRALIS software release
5